@entity731 in premenopausal women with XXXX and @entity1252 : a controlled study.

@entity1 @entity1667 @entity1252 @entity228 @entity1701 @entity9500 @entity134 @entity731 @entity121 @entity309
OBJECTIVE: To evaluate whether premenopausal women with @entity1701 ( @entity1701 ) or @entity1252 ( @entity1252 ) have increased prevalence of @entity731 after adjustment has been made for known cardiovascular risk factors. METHODS: We evaluated premenopausal @entity1 with @entity1701 in comparison with age-matched groups of @entity1 with @entity1252 [positive or negative for anticardiolipin (aCL) antibodies] or @entity309 ( @entity309 ), and healthy subjects. Thirty-three subjects in each group were assessed for cardiovascular risk factors, including a detailed lipid profile. Ultrasonography of carotid and femoral arteries assessed the @entity121 ( @entity121 ) and the presence of @entity731 . RESULTS: @entity731 were detected in 5, 2, 4, 1 and 1 subject in the five groups respectively. @entity1701 @entity1 had significantly more affected vessels than @entity309 @entity1 and healthy controls (P=0.042 and P=0.016, respectively), but not compared with @entity1252 @entity1 . No consistent differences in @entity121 , traditional cardiovascular risk factors or lipid parameters were detected among the five groups. The odds for @entity731 independently increased 1.19-fold per year of increasing age [95% confidence interval (CI) 1.08-1.31; P=0.001), 1.019-fold per 1 mg/dl increase in low-density lipoprotein (LDL) (95% CI 1.003-1.036; P=0.020), 1.035-fold per additional 1 g of @entity1667 equivalent cumulative @entity228 dose (95% CI, 0.996-1.074; P=0.074), and 4.35-fold in the presence of @entity1701 or @entity1252 (95% CI 0.75-25.2; P=0.10). Neither aCL nor anti- @entity9500 antibodies were associated with @entity731 . CONCLUSION: @entity1701 and @entity1252 @entity1 have an increased prevalence of carotid and femoral plaque that is not accounted for by other predictors of @entity731 , including age, lipid parameters and cumulative @entity134 dose.
